Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine.
Fukushima J Med Sci
; 68(1): 67-70, 2022 Apr 08.
Article
in English
| MEDLINE | ID: covidwho-1975228
ABSTRACT
This study investigated the immune response and outcome of BNT162b2 vaccination among 12 staff at a hospital in Fukushima, Japan. Blood samples were collected from participants before their first vaccination, with subsequent sampling performed during the participants' work days for six weeks thereafter. Antibody titers peaked 6-13 days after the second vaccination (days 27-34 after the first), followed by a steady decrease. Six males had significantly lower peak antibody titers than six females (p = 0.016 with t-test); the older six (median age 53 years) had lower antibody titers than the younger six (median age 35 years) but without statistical significance (p value=0.24 with t-test).
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Immunoglobulin G
/
Spike Glycoprotein, Coronavirus
/
SARS-CoV-2
/
COVID-19
/
BNT162 Vaccine
/
Antibodies, Viral
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Fukushima J Med Sci
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS